

May 14, 2019

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Scrip Code: 532296

Scrip Name: GLENMARK

Ref: Your emails dated May 13, 2019

Dear Sirs,

Sub: Clarification on news item appeared in <https://economictimes.indiatimes.com> dated 13th May, 2019, titled "Pharma stocks bleed as US states file lawsuit against generic drug firms"

This has reference to your above emails seeking clarification on the subject matter.

In this regard, we have to inform you that in December 2016, the Attorney General of the State of Connecticut along with the Attorneys' General of various other U.S. states filed for leave to amend an existing lawsuit in Federal Court to allege that the companies in the US generic drug industry including Glenmark had violated antitrust laws by fixing prices and allocating customers. On 5th June, 2018, leave to file the Amended Complaint was granted in the first State AG Action. The Company has denied all the relevant accusations in the first State AG Action and is vigorously defending the matter.

On 10th May, 2019, the Attorney General of the State of Connecticut and Attorneys' General of various U.S. states filed a second lawsuit in Federal Court with similar allegations. The Second law suit includes some of the parties from the first State AG Action as well as additional parties, and its allegations concern additional products which were not referenced in the first law suit. While the Company is currently reviewing the Second suit, we expect to file papers with the Federal Court in due course denying the accusations. Given the early nature of the matter, the Company does not anticipate material impact of the same.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited



Harish Kuber
Company Secretary & Compliance Officer